CN108719988B - Coenzyme Q10 clathrate and preparation process thereof - Google Patents
Coenzyme Q10 clathrate and preparation process thereof Download PDFInfo
- Publication number
- CN108719988B CN108719988B CN201810554823.7A CN201810554823A CN108719988B CN 108719988 B CN108719988 B CN 108719988B CN 201810554823 A CN201810554823 A CN 201810554823A CN 108719988 B CN108719988 B CN 108719988B
- Authority
- CN
- China
- Prior art keywords
- coenzyme
- clathrate
- powder
- juice
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 223
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 223
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 223
- 229940110767 coenzyme Q10 Drugs 0.000 title claims abstract description 223
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 87
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000003085 diluting agent Substances 0.000 claims abstract description 48
- 238000001035 drying Methods 0.000 claims abstract description 47
- 239000007787 solid Substances 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims description 131
- 239000000243 solution Substances 0.000 claims description 129
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 71
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 39
- 238000003756 stirring Methods 0.000 claims description 35
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 25
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 23
- 239000001116 FEMA 4028 Substances 0.000 claims description 22
- 229960004853 betadex Drugs 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 20
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 19
- 229930195725 Mannitol Natural products 0.000 claims description 19
- 239000000796 flavoring agent Substances 0.000 claims description 19
- 235000013355 food flavoring agent Nutrition 0.000 claims description 19
- 239000000594 mannitol Substances 0.000 claims description 19
- 235000010355 mannitol Nutrition 0.000 claims description 19
- 229920002472 Starch Polymers 0.000 claims description 18
- 239000008107 starch Substances 0.000 claims description 18
- 229940032147 starch Drugs 0.000 claims description 18
- 235000019698 starch Nutrition 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 17
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 16
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 16
- 229940013618 stevioside Drugs 0.000 claims description 16
- 235000019202 steviosides Nutrition 0.000 claims description 16
- 238000004090 dissolution Methods 0.000 claims description 14
- 238000000227 grinding Methods 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- 239000000853 adhesive Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 235000019441 ethanol Nutrition 0.000 claims description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 12
- 235000010356 sorbitol Nutrition 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 12
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 11
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 11
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 235000015165 citric acid Nutrition 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 9
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 8
- 235000005979 Citrus limon Nutrition 0.000 claims description 8
- 244000131522 Citrus pyriformis Species 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 229920000715 Mucilage Polymers 0.000 claims description 8
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000004570 mortar (masonry) Substances 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 238000009210 therapy by ultrasound Methods 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 108010011485 Aspartame Proteins 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004368 Modified starch Substances 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000605 aspartame Substances 0.000 claims description 6
- 235000010357 aspartame Nutrition 0.000 claims description 6
- 229960003438 aspartame Drugs 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 6
- 229960001631 carbomer Drugs 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 235000019264 food flavour enhancer Nutrition 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000001630 malic acid Substances 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000019426 modified starch Nutrition 0.000 claims description 6
- 235000020374 simple syrup Nutrition 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 5
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 5
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 4
- 244000298697 Actinidia deliciosa Species 0.000 claims description 4
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims description 4
- 241001116389 Aloe Species 0.000 claims description 4
- 240000007087 Apium graveolens Species 0.000 claims description 4
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 4
- 235000010591 Appio Nutrition 0.000 claims description 4
- 241000416162 Astragalus gummifer Species 0.000 claims description 4
- 241001313855 Bletilla Species 0.000 claims description 4
- 235000004936 Bromus mango Nutrition 0.000 claims description 4
- 240000004160 Capsicum annuum Species 0.000 claims description 4
- 240000008384 Capsicum annuum var. annuum Species 0.000 claims description 4
- 235000009467 Carica papaya Nutrition 0.000 claims description 4
- 240000006432 Carica papaya Species 0.000 claims description 4
- 244000241235 Citrullus lanatus Species 0.000 claims description 4
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims description 4
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 4
- 229920002907 Guar gum Polymers 0.000 claims description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 240000007472 Leucaena leucocephala Species 0.000 claims description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 4
- 235000014826 Mangifera indica Nutrition 0.000 claims description 4
- 240000007228 Mangifera indica Species 0.000 claims description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- 239000004384 Neotame Substances 0.000 claims description 4
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 4
- 244000288157 Passiflora edulis Species 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- 240000000111 Saccharum officinarum Species 0.000 claims description 4
- 235000007201 Saccharum officinarum Nutrition 0.000 claims description 4
- 239000001744 Sodium fumarate Substances 0.000 claims description 4
- 235000009184 Spondias indica Nutrition 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 229920001615 Tragacanth Polymers 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 4
- 244000273928 Zingiber officinale Species 0.000 claims description 4
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 claims description 4
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 4
- 229960004998 acesulfame potassium Drugs 0.000 claims description 4
- 239000000619 acesulfame-K Substances 0.000 claims description 4
- 229960003767 alanine Drugs 0.000 claims description 4
- 235000011399 aloe vera Nutrition 0.000 claims description 4
- 235000015197 apple juice Nutrition 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
- 235000015190 carrot juice Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000013330 chicken meat Nutrition 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 229960000913 crospovidone Drugs 0.000 claims description 4
- 235000020379 cucumber juice Nutrition 0.000 claims description 4
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 4
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 claims description 4
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 4
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 claims description 4
- 235000013896 disodium guanylate Nutrition 0.000 claims description 4
- 239000004198 disodium guanylate Substances 0.000 claims description 4
- 235000013890 disodium inosinate Nutrition 0.000 claims description 4
- 239000004194 disodium inosinate Substances 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 229960002737 fructose Drugs 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000008397 ginger Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229960001031 glucose Drugs 0.000 claims description 4
- 229960002449 glycine Drugs 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 235000019674 grape juice Nutrition 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000011477 liquorice Nutrition 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 229960001855 mannitol Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 4
- 235000019412 neotame Nutrition 0.000 claims description 4
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 4
- 108010070257 neotame Proteins 0.000 claims description 4
- 235000015205 orange juice Nutrition 0.000 claims description 4
- 235000015206 pear juice Nutrition 0.000 claims description 4
- 235000013997 pineapple juice Nutrition 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 229940113124 polysorbate 60 Drugs 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 239000000473 propyl gallate Substances 0.000 claims description 4
- 235000010388 propyl gallate Nutrition 0.000 claims description 4
- 229940075579 propyl gallate Drugs 0.000 claims description 4
- 229940085605 saccharin sodium Drugs 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000015424 sodium Nutrition 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229940083542 sodium Drugs 0.000 claims description 4
- 229960001462 sodium cyclamate Drugs 0.000 claims description 4
- 235000019294 sodium fumarate Nutrition 0.000 claims description 4
- 229940005573 sodium fumarate Drugs 0.000 claims description 4
- 229940073490 sodium glutamate Drugs 0.000 claims description 4
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims description 4
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 claims description 4
- 235000020384 spinach juice Nutrition 0.000 claims description 4
- 235000013948 strawberry juice Nutrition 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000015193 tomato juice Nutrition 0.000 claims description 4
- 235000010487 tragacanth Nutrition 0.000 claims description 4
- 239000000196 tragacanth Substances 0.000 claims description 4
- 229940116362 tragacanth Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- OOCMUZJPDXYRFD-UHFFFAOYSA-L calcium;2-dodecylbenzenesulfonate Chemical compound [Ca+2].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O OOCMUZJPDXYRFD-UHFFFAOYSA-L 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 229940107161 cholesterol Drugs 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 229960002598 fumaric acid Drugs 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 229960001285 quercetin Drugs 0.000 claims description 2
- 235000020748 rosemary extract Nutrition 0.000 claims description 2
- 229940092258 rosemary extract Drugs 0.000 claims description 2
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 claims description 2
- 229940082004 sodium laurate Drugs 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 229950006451 sorbitan laurate Drugs 0.000 claims description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 2
- 229950004959 sorbitan oleate Drugs 0.000 claims description 2
- 229950011392 sorbitan stearate Drugs 0.000 claims description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 2
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229950003429 sorbitan palmitate Drugs 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- 239000005515 coenzyme Substances 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 description 24
- 229960004106 citric acid Drugs 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 6
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 6
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- CUJVBAPGYBSBHJ-YWBSARSQSA-N 2-[[(1R,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21R,23R,25R,26R,28R,30R,31R,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,38,40,42-tetrakis(carboxymethoxy)-10,15-bis(carboxymethoxymethyl)-37,39,41,43,44,45,46,47,48,49-decahydroxy-20,25,30,35-tetrakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]acetic acid Chemical compound OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](OCC(O)=O)[C@H]2O)[C@H](O)[C@H]5OCC(O)=O)[C@H](O)[C@H]4OCC(O)=O)[C@H](O)[C@H]3OCC(O)=O CUJVBAPGYBSBHJ-YWBSARSQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- -1 quinone compound Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a coenzyme Q10 clathrate and a preparation process thereof, belonging to the fields of food, medicine and health care products. A coenzyme Q10 clathrate compound is prepared from the following components in parts by weight: 0.5-8 parts of coenzyme Q10, 1-10 parts of cyclodextrin and 50-600 parts of hydrophilic diluent. The invention has the advantages that: the hydrophilic diluent with reasonable dosage is used, so that nonpolar coenzyme Q10 molecules are repelled by the hydrophilic diluent and can be better kept in a cyclodextrin cavity, the proportion of coenzyme Q10 molecules separated from cyclodextrin in the drying process of the clathrate is reduced, the inclusion rate of the coenzyme Q10-cyclodextrin clathrate is improved, and the stability of the coenzyme Q10 in a solid state is further improved.
Description
Technical Field
The invention relates to a coenzyme Q10 clathrate and a preparation process thereof, belongs to the field of food, medicine and health care products, and particularly relates to a water-soluble clathrate containing coenzyme Q10 and a preparation process thereof.
Background
Coenzyme Q10 exists in the inner membrane of mitochondria of many higher animals and plants, participates in energy production and activation in human cells, is a natural antioxidant and a cell metabolism promoter produced by cells, has the functions of protecting and restoring the integrity of a biological membrane structure and stabilizing membrane potential, and is a non-specific immunopotentiator of organisms. Coenzyme Q10 is an effective antioxidant and free radical scavenger, and can inhibit the modification of free radicals on receptor and cell differentiation activity related microtubule system on immune cells, enhance immune system, and delay aging. The coenzyme Q10 can penetrate into cells, enhance the metabolism function of the cells, activate the bonding ability between cells, repair wrinkles caused by water loss, and further achieve the real moisturizing effect. The coenzyme Q10 can improve the function of cardiac muscle, is widely applied to cardiovascular diseases, is beneficial to providing sufficient oxygen for cardiac muscle and preventing sudden heart disease, especially plays a key role in the process of myocardial anoxia, and has good therapeutic effects on metabolic cardiotonic and left ventricular hypertrophy reversal. Coenzyme Q10 also has antitumor and antihypertensive effects.
Coenzyme Q10 can be obtained from food, but sometimes the amount obtained from food is not sufficient for human needs, and therefore coenzyme Q10 dietary supplement products can be consumed. Coenzyme Q10 is a fat-soluble quinone compound, is difficult to dissolve in water, is unstable to light, heat and water, and has low bioavailability in oral administration, and in order to overcome the defect, various technologies for preparing the clathrate compound from coenzyme Q10 have been developed in recent years. An invention patent with the patent publication number of CN101053556A and the name of water-soluble coenzyme Q10 hydroxypropyl-beta-cyclodextrin inclusion compound and a preparation method thereof introduces the coenzyme Q10 to be contained by taking hydroxypropyl-beta-cyclodextrin as cyclodextrin, and the coenzyme Q10 inclusion compound is prepared by drying, but the weight ratio of the hydroxypropyl-beta-cyclodextrin to the coenzyme Q10 is large in the invention. The existing inclusion technology for preparing coenzyme Q10 inclusion compound has the disadvantages of large cyclodextrin dosage and small effective medicine dosage. In addition, in the existing inclusion technology, coenzyme Q10 is added into a cyclodextrin aqueous solution, nonpolar coenzyme Q10 molecules repel polar water molecules, so that coenzyme Q10 molecules can stably exist in a cyclodextrin molecular cavity, but in the process of drying the inclusion compound solution, a large amount of water molecules are reduced, the repulsive force borne by coenzyme Q10 is also greatly reduced, the stable environment that the coenzyme Q10 exists in the cyclodextrin cavity is destroyed, a part of coenzyme Q10 molecules are separated from the cyclodextrin cavity, not only the coenzyme Q10 molecules are combined with each other to form precipitates, but also the inclusion rate of the coenzyme Q10-cyclodextrin inclusion compound is low.
Disclosure of Invention
In order to solve the technical problems, the invention provides a coenzyme Q10 clathrate and a preparation process thereof, wherein in the drying process of the coenzyme Q10 clathrate, the proportion of coenzyme Q10 molecules separated from cyclodextrin is reduced, and the inclusion rate of the coenzyme Q10-cyclodextrin clathrate is improved.
In order to achieve the purpose, the invention adopts the following technical scheme:
a coenzyme Q10 clathrate compound is prepared from the following components in parts by weight: 0.5-8 parts of coenzyme Q10, 1-10 parts of cyclodextrin and 50-600 parts of hydrophilic diluent.
Preferably, the coenzyme Q10 clathrate compound is prepared from the following components in parts by weight: 1-5 parts of coenzyme Q10, 3-8 parts of cyclodextrin and 100-550 parts of hydrophilic diluent.
Further preferably, the coenzyme Q10 clathrate compound is prepared from the following components in parts by weight: 3 parts by weight of coenzyme Q10, 5 parts by weight of cyclodextrin and 492 parts by weight of hydrophilic diluent.
The hydrophilic diluent is selected from one or more of sorbitol, mannitol, dextrin, starch and collagen.
The cyclodextrin is selected from one or more of beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin, sulfobutyl ether-beta-cyclodextrin, carboxymethyl-beta-cyclodextrin, methyl-beta-cyclodextrin, hydroxybutyl-beta-cyclodextrin, p-toluenesulfonyl-beta-cyclodextrin, alpha-cyclodextrin, hydroxypropyl-alpha-cyclodextrin and gamma-cyclodextrin.
Preferably, the cyclodextrin is selected from one or more of beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin and gamma-cyclodextrin.
In order to reduce the rate of coenzyme Q10 molecules separating from cyclodextrin in the drying process of the clathrate compound and improve the inclusion rate of the coenzyme Q10-cyclodextrin clathrate compound, a large number of experiments are carried out, and experimental data are analyzed and researched. Analysis and research show that by adopting the process and the formula of the invention and using 50-600 parts by weight of hydrophilic diluent, the reduction degree of the inclusion rate of the coenzyme Q10 inclusion compound in the drying process can be greatly reduced. Because the nonpolar coenzyme Q10 molecule is repelled from the polar water molecule in the presence of water, the coenzyme Q10 molecule is more stable to stay inside the cyclodextrin; in the drying process, polar water molecules are rapidly reduced, the stability of the coenzyme Q10 molecules in the cyclodextrin is relatively reduced, part of the coenzyme Q10 molecules are separated from the cyclodextrin, and the inclusion rate is reduced. If a hydrophilic diluent is contained in the clathrate solution, even if water molecules are rapidly reduced upon concentration and drying, the polar hydrophilic diluent is not reduced. The nonpolar coenzyme Q10 molecule is repelled by the hydrophilic diluent and can be better kept in the cyclodextrin cavity, thereby achieving higher entrapment efficiency and further improving the stability of the coenzyme Q10 in a solid state.
The amount of hydrophilic diluent used in drying the clathrate solution is optimal for the scope of the present invention. The dosage of the hydrophilic diluent is too low, the repulsive force to coenzyme Q10 molecules is small, and the situation that the coenzyme Q10 molecules are stably arranged in the cyclodextrin cavity cannot be achieved, so that the inclusion rate is reduced; if the hydrophilic diluent is used in an excessively high amount, the amount of cyclodextrin inclusion compound dissolved decreases, thereby decreasing the inclusion rate.
Furthermore, the coenzyme Q10 clathrate also contains 0.1-2 weight parts of antioxidant.
Further, the antioxidant is selected from one or more of butylated hydroxyanisole, butylated hydroxytoluene, tertiary butyl hydroquinone, vitamin E, rosemary extract, propyl gallate, quercetin, ascorbic acid, ascorbyl palmitate, and tea polyphenol.
Furthermore, the coenzyme Q10 clathrate also comprises one or more of 40-320 parts by weight of filler, 3-30 parts by weight of adhesive, 3-35 parts by weight of wetting agent, 6-50 parts by weight of disintegrant, 3-32 parts by weight of lubricant and 6-100 parts by weight of flavoring agent.
Further, the filler is selected from one or more of microcrystalline cellulose, polyethylene glycol 4000, polyethylene glycol 6000, mannitol, sorbitol, dextrin, lactose, compressible starch and modified starch; the adhesive is selected from one or more of hydroxypropyl methylcellulose, sodium carboxymethylcellulose, polyvidone, methylcellulose, hydroxypropyl cellulose, ethyl cellulose, gelatin, carbomer or starch slurry; the wetting agent is selected from water or 30-70% ethanol water solution; the disintegrating agent is selected from one or more of crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, sodium starch glycolate, sodium carboxymethyl starch, calcium carboxymethyl cellulose and sodium alginate; the lubricant is selected from one or more of stearic acid, micronized poloxamer, sodium fumarate stearate, sodium lauryl sulfate, polyethylene glycol, sodium lauryl sulfate, magnesium lauryl sulfate, fumaric acid, sodium fumarate, talcum powder, superfine silica gel powder, magnesium stearate and silicon dioxide; the flavoring agent is one or more selected from acidic flavoring agent, sweetener, flavor enhancer, essence, natural fruit and vegetable juice powder, mucilage and milk product.
Further, the acidic flavoring agent is selected from one or two of vitamin C, malic acid and citric acid; the sweetener is selected from one or more of saccharin sodium, stevioside, aspartame, neotame, honey, sucralose, sodium cyclamate, liquorice, acesulfame potassium, tagatose, disodium glycyrrhizinate, glucose, fructose, sucrose, xylitol, simple syrup and fruit syrup; the flavor enhancer is selected from one or more of sodium glutamate, aspartic acid, glycine, L-alanine, disodium succinate, disodium guanylate, disodium inosinate and chicken essence; the essence is selected from one or more of water-soluble natural essence, water-soluble synthetic essence, water-soluble natural equivalent essence and water-soluble fermented essence; the natural fruit and vegetable juice powder is selected from one or more of lemon juice powder, mint juice powder, ginger juice powder, orange juice powder, pineapple juice powder, pear juice powder, watermelon juice powder, apple juice powder, cucumber juice powder, grape juice powder, kiwi juice powder, passion fruit juice powder, strawberry juice powder, mango juice powder, sugarcane juice powder, papaya juice powder, aloe juice powder, tomato juice powder, celery juice powder, spinach juice powder, carrot juice powder, sweet pepper juice powder and green pepper juice powder; the mucilage is selected from one or more of sodium carboxymethylcellulose, methylcellulose, guar gum, acacia, tragacanth, xanthan gum, bletilla hyacinthine starch, carbomer, polyvinyl alcohol, polyvidone and gelatin.
The solid preparation containing the coenzyme Q10 inclusion compound is one of powder, tablets, granules and capsules.
The solution preparation containing the coenzyme Q10 clathrate also contains 1000-100000 parts by weight of edible solvent.
The edible solvent is selected from one or more of water, glycerol, ethanol and mannitol.
The solution preparation also contains 0.5-10 parts by weight of emulsifier and/or 6-100 parts by weight of flavoring agent.
In the solution preparation, the emulsifier is selected from one or more of egg yolk lecithin, soybean lecithin, poloxamer 188, sorbitan laurate, sorbitan palmitat, sorbitan stearate, sorbitan oleate, sorbitan trioleate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, cholesterol, sodium dodecyl sulfate, sodium dodecyl benzene sulfonate, calcium dodecyl benzene sulfonate, sodium stearate, sodium oleate and sodium laurate; the flavoring agent is one or more selected from acidic flavoring agent, sweetener, flavoring agent, essence, natural fruit and vegetable juice, mucilage and milk product.
The acidic flavoring agent is one or two of vitamin C, malic acid and citric acid; the sweetener is selected from one or more of saccharin sodium, stevioside, aspartame, neotame, honey, sucralose, sodium cyclamate, liquorice, acesulfame potassium, tagatose, disodium glycyrrhizinate, glucose, fructose, sucrose, xylitol, simple syrup and fruit syrup; the flavor enhancer is selected from one or more of sodium glutamate, aspartic acid, glycine, L-alanine, disodium succinate, disodium guanylate, disodium inosinate and chicken essence; the essence is selected from one or more of water-soluble natural essence, water-soluble synthetic essence, water-soluble natural equivalent essence and water-soluble fermented essence; the natural fruit and vegetable juice is selected from one or more of lemon juice, mint juice, ginger juice, orange juice, pineapple juice, pear juice, watermelon juice, apple juice, cucumber juice, grape juice, kiwi fruit juice, passion fruit juice, strawberry juice, mango juice, sugarcane juice, papaya juice, aloe juice, tomato juice, celery juice, spinach juice, carrot juice, sweet pepper juice and green pepper juice; the mucilage is selected from one or more of sodium carboxymethylcellulose, methylcellulose, guar gum, acacia, tragacanth, xanthan gum, bletilla hyacinthine starch, carbomer, polyvinyl alcohol, polyvidone and gelatin.
A preparation process of a coenzyme Q10 clathrate compound comprises the following steps:
(1) an ultrasonic method: adding coenzyme Q10 into a saturated aqueous solution containing cyclodextrin, performing ultrasonic treatment for 5-15 minutes by using an ultrasonic disruptor to accelerate the dissolution of coenzyme Q10 to prepare an inclusion compound solution, adding a hydrophilic diluent into the inclusion compound solution, washing and drying to obtain coenzyme Q10 inclusion compound powder;
(2) saturated aqueous solution method: adding coenzyme Q10 into saturated cyclodextrin water solution, stirring with an electric stirrer at 50 deg.C for 30-60 min to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding hydrophilic diluent into the clathrate solution, washing, and drying to obtain coenzyme Q10 clathrate powder;
(3) grinding method: adding cyclodextrin into water, grinding with a mortar, adding ethanol solution containing coenzyme Q10 into the mortar, grinding to obtain paste, adding hydrophilic diluent into the paste, cleaning, and drying to obtain coenzyme Q10 clathrate powder;
(4) spray drying method: adding coenzyme Q10 into cyclodextrin water solution, stirring thoroughly to obtain clathrate solution with coenzyme Q10 being wrapped, adding hydrophilic diluent into clathrate solution, and drying the solution into coenzyme Q10 clathrate powder under spray condition;
(5) freeze drying: dissolving coenzyme Q10 and cyclodextrin in water, stirring to dissolve the coenzyme Q10 and the cyclodextrin to obtain an inclusion compound solution, adding a hydrophilic diluent into the inclusion compound solution, and subliming water by cooling and reducing pressure to obtain dry inclusion compound powder of coenzyme Q10;
(6) fluidized bed drying method: sequentially adding coenzyme Q10 into cyclodextrin aqueous solution, fully stirring to prepare an inclusion compound solution containing coenzyme Q10, spraying the inclusion compound solution onto a hydrophilic diluent through a fluidized bed dryer, and simultaneously drying the coenzyme Q10 inclusion compound to obtain coenzyme Q10 inclusion compound powder;
the coenzyme Q10 clathrate powder obtained above can be made into powder, tablet, granule or capsule.
The preparation method of the solid preparation containing the coenzyme Q10 clathrate compound comprises the steps of adding one or more of antioxidant, filler, adhesive, wetting agent, disintegrant, lubricant and flavoring agent into the prepared coenzyme Q10 clathrate compound powder, mixing, and preparing into powder, tablets, granules or capsules.
The preparation method of the solution preparation containing the coenzyme Q10 clathrate comprises the steps of adding the powder of the prepared coenzyme Q10 inclusion compound into an edible solvent, and uniformly mixing to prepare a solution;
or adding the above powder of coenzyme Q10 inclusion, antioxidant and correctant into edible solvent, mixing, adding required emulsifier, and mixing to obtain solution.
The invention has the advantages that: the hydrophilic diluent with reasonable dosage is used, so that nonpolar coenzyme Q10 molecules are repelled by the hydrophilic diluent and can be better kept in a cyclodextrin cavity, the proportion of coenzyme Q10 molecules separated from cyclodextrin in the drying process of the clathrate is reduced, the inclusion rate of the coenzyme Q10-cyclodextrin clathrate is improved, and the stability of the coenzyme Q10 in a solid state is further improved.
Detailed Description
Example 1
The formula is as follows: 0.5g coenzyme Q10; 3g hydroxypropyl-beta-cyclodextrin; 50g of mannitol
The process comprises the following steps: adding coenzyme Q10 into saturated hydroxypropyl-beta-cyclodextrin water solution, stirring with an electric stirrer at 50 deg.C for 30 min to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding mannitol into the clathrate solution, washing, and drying to obtain clathrate powder. And (4) putting the clathrate compound powder into a tablet machine to be pressed into tablets.
Example 2
The formula is as follows: 1g coenzyme Q10; 8g of beta-cyclodextrin; 100g starch
The process comprises the following steps: adding coenzyme Q10 into beta-cyclodextrin water solution, stirring thoroughly to obtain clathrate solution with coenzyme Q10 coated, adding starch into clathrate solution, and drying the solution into clathrate powder under spray condition. Adding the clathrate powder into a granulator to obtain granule, and making into granule.
Example 3
The formula is as follows: 8g coenzyme Q10; 5g sulfobutyl ether-beta-cyclodextrin; 550g of sorbitol
The process comprises the following steps: coenzyme Q10 and sulfobutyl ether-beta-cyclodextrin are dissolved in water, stirred to be dissolved to obtain an inclusion compound solution, sorbitol is added into the inclusion compound solution, and the water is sublimated by reducing the temperature and the pressure to obtain dry inclusion compound powder. Pulverizing the clathrate powder with a grinder to obtain powder.
Example 4
The formula is as follows: 3g coenzyme Q10; 1g of gamma-cyclodextrin; 490g dextrin
The process comprises the following steps: adding gamma-cyclodextrin into water, grinding with a mortar, adding ethanol solution containing coenzyme Q10 into the mortar, grinding to obtain paste, adding dextrin into the paste, cleaning, and drying to obtain clathrate powder. Adding the clathrate powder into a granulator to obtain granules, and placing the granules into a tablet machine to be pressed into tablets.
Example 5
The formula is as follows: 5g coenzyme Q10; 10g of alpha-cyclodextrin; 600g collagen
The process comprises the following steps: adding coenzyme Q10 into saturated aqueous solution containing alpha-cyclodextrin, performing ultrasonic treatment for 5 minutes by using an ultrasonic disruptor to accelerate the dissolution of coenzyme Q10 to prepare an inclusion compound solution, adding collagen into the inclusion compound solution, washing and drying to obtain inclusion compound powder. Adding the clathrate powder into a granulator to obtain granule, and encapsulating to obtain capsule.
Example 6
The formula is as follows: 3g coenzyme Q10; 5g of gamma-cyclodextrin; 492g of mannitol; 0.1g vitamin E
The process comprises the following steps: dissolving coenzyme Q10 and gamma-cyclodextrin in water, stirring to dissolve to obtain clathrate solution, adding mannitol into the clathrate solution, and subliming water by cooling and lowering pressure to obtain dry clathrate powder. Mixing the clathrate powder and vitamin E, stirring to obtain mixture, and adding the mixture into granulator to obtain granule.
Example 7
The formula is as follows: 5g coenzyme Q10; 8g sulfobutyl ether-beta-cyclodextrin; 400g of dextrin; 2g of dibutylhydroxytoluene; 40g lactose
The process comprises the following steps: adding coenzyme Q10 into sulfobutyl ether-beta-cyclodextrin water solution, stirring thoroughly to obtain clathrate solution with coenzyme Q10, adding dextrin into the clathrate solution, and drying the solution into clathrate powder under spray condition. Mixing clathrate powder, dibutyl hydroxy toluene, and lactose, stirring to obtain mixture, and grinding the mixture with grinder into powder.
Example 8
The formula is as follows: 0.5g coenzyme Q10; 5g beta-cyclodextrin; 100g of collagen; 1g ascorbic acid; 1000g of water; 10g polysorbate 60; 10g simple syrup
The process comprises the following steps: adding coenzyme Q10 into saturated beta-cyclodextrin water solution, stirring with an electric stirrer at 50 deg.C for 60 min to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding collagen into the clathrate solution, washing, and drying to obtain clathrate powder. Adding the clathrate powder, ascorbic acid, polysorbate 60, and simple syrup into water, mixing, and making into solution.
Example 9
The formula is as follows: 8g coenzyme Q10; 10g hydroxypropyl-beta-cyclodextrin; 550g of starch; 0.1 butyl hydroxyanisole; 320g of microcrystalline cellulose; 30g sodium carboxymethylcellulose; 50g of low-substituted hydroxypropylcellulose; 20g of stearic acid; 30g of vitamin C; 20g of fructose
The process comprises the following steps: sequentially adding coenzyme Q10 into hydroxypropyl-beta-cyclodextrin aqueous solution, fully stirring to prepare an inclusion compound solution containing coenzyme Q10, spraying the inclusion compound solution onto starch through a fluidized bed dryer, and simultaneously drying the coenzyme Q10 inclusion compound to obtain inclusion compound powder. Mixing clathrate powder, butyl hydroxy anisole, microcrystalline cellulose, sodium carboxymethylcellulose, low-substituted hydroxypropyl cellulose, stearic acid, vitamin C, and fructose, stirring to obtain mixture, adding the mixture into granulator to obtain granule, and making into granule.
Example 10
The formula is as follows: 1g coenzyme Q10; 8g of alpha-cyclodextrin; 50g of mannitol; 1.5g tea polyphenols; 40g of polyethylene glycol 4000; 23g of hydroxypropylmethylcellulose; 3g of water; 35g of crospovidone; 10g of micronized poloxamer; 6g of aspartame
The process comprises the following steps: dissolving coenzyme Q10 and alpha-cyclodextrin in water, stirring to dissolve to obtain clathrate solution, adding mannitol into the clathrate solution, and subliming water by cooling and lowering pressure to obtain dry clathrate powder. Mixing the clathrate powder, tea polyphenols, polyethylene glycol 4000, hydroxypropyl methylcellulose, water, crospovidone, micronized poloxamer and aspartame, stirring to obtain mixture, and pressing the mixture into tablet.
Example 11
The formula is as follows: 5g coenzyme Q10; 3g beta-cyclodextrin; 600g of dextrin; 1g of tert-butylhydroquinone; 320g of modified starch; 3g sodium fumarate stearate; 80g lemon juice powder
The process comprises the following steps: adding coenzyme Q10 into saturated beta-cyclodextrin water solution, stirring with an electric stirrer at 50 deg.C for 30 min to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding dextrin into the clathrate solution, washing, and drying to obtain clathrate powder. Mixing clathrate powder, tert-butyl hydroquinone, modified starch, sodium fumarate and lemon juice powder, stirring to obtain mixture, and grinding the mixture with grinder to obtain powder.
Example 12
The formula is as follows: 3g coenzyme Q10; 1g of gamma-cyclodextrin; 350g of collagen; 2g propyl gallate; 200g of polyethylene glycol 6000; 35g of a 30% ethanol aqueous solution; 6g sodium carboxymethyl starch; 20g magnesium stearate; 12g of silica; 70g of malic acid; 30g of sucrose
The process comprises the following steps: dissolving coenzyme Q10 and gamma-cyclodextrin in water, stirring to dissolve to obtain clathrate solution, adding collagen into the clathrate solution, and sublimating water by cooling and lowering pressure to obtain dry clathrate powder. Mixing the clathrate powder, propyl gallate, polyethylene glycol 6000, 30% ethanol water solution, sodium carboxymethyl starch, magnesium stearate, silicon dioxide, malic acid, and sucrose, stirring to obtain mixture, and encapsulating.
Example 13
The formula is as follows: 3g coenzyme Q10; 5g beta-cyclodextrin; 492g of mannitol; 0.8g of tert-butylhydroquinone; 80000g of water; 20000g of ethanol; 0.5g sodium lauryl sulfate; 100g of citric acid; 50 stevioside
The process comprises the following steps: adding coenzyme Q10 into saturated water solution containing beta-cyclodextrin, performing ultrasonic treatment for 15 min with an ultrasonic disruptor to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding mannitol into the clathrate solution, washing and drying to obtain clathrate powder. Mixing water and ethanol to obtain ethanol water solution, adding the clathrate powder, tert-butyl hydroquinone, sodium dodecyl sulfate, citric acid and stevioside into the ethanol water solution, and mixing to obtain solution.
Example 14
The formula is as follows: 3g coenzyme Q10; 5g beta-cyclodextrin; 492g of sorbitol; 0.5g of butylated hydroxyanisole; 150g of microcrystalline cellulose; 25g of povidone; 20g croscarmellose sodium; 15g of stearic acid; 20g of water-soluble natural essence; 30g stevioside
The process comprises the following steps: adding coenzyme Q10 into beta-cyclodextrin water solution successively, stirring thoroughly to prepare clathrate solution with coenzyme Q10 being coated, adding sorbitol into clathrate solution, and drying the solution into clathrate powder under spraying condition. Mixing clathrate powder, butyl hydroxy anisol, microcrystalline cellulose, polyvidone, croscarmellose sodium, stearic acid, water soluble natural essence, and stevioside, stirring to obtain mixture, adding the mixture into granulator to obtain granules, and tabletting.
Comparative example 1
The formula is as follows: 3g coenzyme Q10; 5g beta-cyclodextrin; 4000g of mannitol; 0.8g of tert-butylhydroquinone; 80000g of water; 20000g of ethanol; 0.5g sodium lauryl sulfate; 100g of citric acid; 50 stevioside
The process comprises the following steps: adding coenzyme Q10 into saturated water solution containing beta-cyclodextrin, performing ultrasonic treatment for 15 min with an ultrasonic disruptor to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding mannitol into the clathrate solution, washing and drying to obtain clathrate powder. Mixing water and ethanol to obtain ethanol water solution, adding the clathrate powder, tert-butyl hydroquinone, sodium dodecyl sulfate, citric acid and stevioside into the ethanol water solution, and mixing to obtain solution.
Comparative example 2
The formula is as follows: 3g coenzyme Q10; 5g beta-cyclodextrin; 15g of mannitol; 0.8g of tert-butylhydroquinone; 80000g of water; 20000g of ethanol; 0.5g sodium lauryl sulfate; 100g of citric acid; 50 stevioside
The process comprises the following steps: adding coenzyme Q10 into saturated water solution containing beta-cyclodextrin, performing ultrasonic treatment for 15 min with an ultrasonic disruptor to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding mannitol into the clathrate solution, washing and drying to obtain clathrate powder. Mixing water and ethanol to obtain ethanol water solution, adding the clathrate powder, tert-butyl hydroquinone, sodium dodecyl sulfate, citric acid and stevioside into the ethanol water solution, and mixing to obtain solution.
Comparative example 3
The formula is as follows: 3g coenzyme Q10; 5g beta-cyclodextrin; 4000g of sorbitol; 0.5g of butylated hydroxyanisole; 150g of microcrystalline cellulose; 25g of povidone; 20g croscarmellose sodium; 15g of stearic acid; 20g of water-soluble natural essence; 30g stevioside
The process comprises the following steps: adding coenzyme Q10 into beta-cyclodextrin water solution successively, stirring thoroughly to prepare clathrate solution with coenzyme Q10 being coated, adding sorbitol into clathrate solution, and drying the solution into clathrate powder under spraying condition. Mixing clathrate powder, butyl hydroxy anisol, microcrystalline cellulose, polyvidone, croscarmellose sodium, stearic acid, water soluble natural essence, and stevioside, stirring to obtain mixture, adding the mixture into granulator to obtain granules, and tabletting.
Comparative example 4
The formula is as follows: 3g coenzyme Q10; 5g beta-cyclodextrin; 15g of sorbitol; 0.5g of butylated hydroxyanisole; 150g of microcrystalline cellulose; 25g of povidone; 20g croscarmellose sodium; 15g of stearic acid; 20g of water-soluble natural essence; 30g stevioside
The process comprises the following steps: adding coenzyme Q10 into beta-cyclodextrin water solution successively, stirring thoroughly to prepare clathrate solution with coenzyme Q10 being coated, adding sorbitol into clathrate solution, and drying the solution into clathrate powder under spraying condition. Mixing clathrate powder, butyl hydroxy anisol, microcrystalline cellulose, polyvidone, croscarmellose sodium, stearic acid, water soluble natural essence, and stevioside, stirring to obtain mixture, adding the mixture into granulator to obtain granules, and tabletting.
Comparative example 5
The formula is as follows: 3g coenzyme Q10; 5g beta-cyclodextrin; 1g of tert-butylhydroquinone; 320g of modified starch; 3g sodium fumarate stearate; 80g lemon juice powder
The process comprises the following steps: adding coenzyme Q10 into saturated beta-cyclodextrin water solution, stirring with an electric stirrer at 50 ℃ for 30 minutes to accelerate the dissolution of coenzyme Q10 to obtain an inclusion compound solution, and washing and drying the inclusion compound solution to obtain inclusion compound powder. Mixing clathrate powder, tert-butyl hydroquinone, modified starch, sodium fumarate and lemon juice powder, stirring to obtain mixture, and grinding the mixture with grinder to obtain powder.
Example 15 test experiment
The coenzyme Q10 clathrate may be subjected to de-clathration in the drying process, and the de-clathrated coenzyme Q10 molecule and the coenzyme Q10 clathrate are dried simultaneously to form mixed powder which is difficult to separate. When the mixed powder is dissolved in water, the clathrate of coenzyme Q10 is dissolved in water, and the clathrated coenzyme Q10 molecule is not dissolved in water, the clathrated coenzyme Q10 molecule is filtered off, and the weight of the clathrated coenzyme Q10 molecule (M10 molecule) is measured1) And with reference to the amount of coenzyme Q10 starting material used (M)0) The inclusion rate of coenzyme Q10 clathrate was evaluated.
In the detection process, the dosage of the samples of the tested examples and the control examples is calculated by taking the dosage M0-50 mg of the coenzyme Q10 as a reference, and the samples of the tested examples and the control examples are weighed according to the calculated dosageAnd (3) sampling. The following describes the procedure for calculating the amount of the sample to be measured in detail, taking example 1 and example 8 as examples. Example 1 (solid dosage form) the sample contained 0.5g of coenzyme Q10, 3g of hydroxypropyl-beta-cyclodextrin, 50g of mannitol, the total weight of the sample was 53.5g, wherein the coenzyme Q10 was 0.5g, and 50mg of coenzyme Q10 was taken, and the amount of the sample used in example 1 was calculated as follows
This gave 5.35 g. The total weight of the sample of example 8 (liquid dosage form) was 1126.5g, wherein 0.5g of coenzyme Q10 was obtained, and 50mg of coenzyme Q10 was taken, and the sample of example 8 was used
Thus, 112.65g was obtained. Weighed samples of examples and control examples (examples 1-5, examples 6-7, examples 9-12, example 14, and control 3-5) of solid dosage forms were dissolved in water, respectively, and then filtered, and the filtered coenzyme Q10 molecules were dry weighed as M1And calculating the inclusion rate of the coenzyme Q10 clathrate. The weighed samples of examples and comparative examples (example 8, example 13, comparative example 1-2) in the form of solution were directly filtered, and the filtered coenzyme Q10 molecules were dry weighed and recorded as M1And calculating the inclusion rate of the coenzyme Q10 clathrate.
Inclusion rate (%) - (M)0-M1)/M0*100％。
The results of the inclusion rate measurements of 14 examples and 5 controls are reported in Table 1 for the purpose of evaluating the effect of the formulation and process used in the present invention on the inclusion effect of clathrates of coenzyme Q10.
TABLE 1 measurement results of inclusion rate
The data in table 1 reflect the inclusion effects of the samples of the examples and the samples of the control examples, and it can be seen from the data that the inclusion rates of 14 samples of the examples are all greater than 88%, and the inclusion rates of 5 samples of the control examples are 66.7% -72.3%, which are significantly less than the inclusion rates of the samples of the examples. The amount of the hydrophilic diluent in the sample is scientific and reasonable and is within the protection scope of the invention; the amount of the hydrophilic diluent of the comparative example exceeds the protection range of the present invention, and some of the samples are too high, some of the samples are too low, and some of the samples do not contain the hydrophilic diluent. Analysis revealed that the hydrophilic diluent had a large effect on the clathrate powder of coenzyme Q10.
In conclusion, the invention uses the hydrophilic diluent with reasonable dosage, thereby greatly improving the inclusion rate of the coenzyme Q10 inclusion compound in the drying process. Under the condition of water, nonpolar coenzyme Q10 molecules are mutually repelled with polar water molecules, and coenzyme Q10 molecules are more stable to stay in the cyclodextrin; in the drying process, polar water molecules are rapidly reduced, the stability of the coenzyme Q10 molecules in the cyclodextrin is relatively reduced, part of the coenzyme Q10 molecules are separated from the cyclodextrin, and the inclusion rate is reduced. If a hydrophilic diluent is contained in the clathrate solution, water molecules are rapidly reduced upon concentration and drying, but polar hydrophilic diluent is not reduced. The nonpolar coenzyme Q10 molecule is repelled by the hydrophilic diluent and can be better kept in the cyclodextrin cavity, thereby achieving higher entrapment efficiency and improving the stability of the coenzyme Q10 in a solid state. The use amount of the hydrophilic diluent is too low, the repulsive force to coenzyme Q10 molecules is small, and the stable environment of the coenzyme Q10 clathrate compound cannot be achieved; if the dosage of the hydrophilic diluent is too high, the hydrophilic diluent can compete with cyclodextrin for aqueous solution, so that the dissolving amount of the cyclodextrin is reduced, and the inclusion rate is reduced; therefore, the amount of hydrophilic diluent is most effective within the scope of the present invention.
Claims (16)
1. A coenzyme Q10 clathrate compound is characterized by being prepared from the following components in parts by weight: 3 parts by weight of coenzyme Q10, 5 parts by weight of cyclodextrin and 492 parts by weight of hydrophilic diluent; the hydrophilic diluent is selected from one or more of sorbitol, mannitol, dextrin, starch and collagen;
the coenzyme Q10 clathrate is prepared by any one of the following methods:
(1) an ultrasonic method: adding coenzyme Q10 into a saturated aqueous solution containing cyclodextrin, performing ultrasonic treatment for 5-15 minutes by using an ultrasonic disruptor to accelerate the dissolution of coenzyme Q10 to prepare an inclusion compound solution, adding a hydrophilic diluent into the inclusion compound solution, washing and drying to obtain coenzyme Q10 inclusion compound powder;
(2) saturated aqueous solution method: adding coenzyme Q10 into saturated cyclodextrin water solution, stirring with an electric stirrer at 50 deg.C for 30-60 min to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding hydrophilic diluent into the clathrate solution, washing, and drying to obtain coenzyme Q10 clathrate powder;
(3) grinding method: adding cyclodextrin into water, grinding with a mortar, adding ethanol solution containing coenzyme Q10 into the mortar, grinding to obtain paste, adding hydrophilic diluent into the paste, cleaning, and drying to obtain coenzyme Q10 clathrate powder;
(4) spray drying method: adding coenzyme Q10 into cyclodextrin water solution, stirring thoroughly to obtain clathrate solution with coenzyme Q10 being wrapped, adding hydrophilic diluent into clathrate solution, and drying the solution into coenzyme Q10 clathrate powder under spray condition;
(5) freeze drying: dissolving coenzyme Q10 and cyclodextrin in water, stirring to dissolve the coenzyme Q10 and the cyclodextrin to obtain an inclusion compound solution, adding a hydrophilic diluent into the inclusion compound solution, and subliming water by cooling and reducing pressure to obtain dry inclusion compound powder of coenzyme Q10;
(6) fluidized bed drying method: adding coenzyme Q10 into cyclodextrin water solution successively, stirring thoroughly to obtain clathrate solution containing coenzyme Q10, spraying the clathrate solution onto hydrophilic diluent by fluidized bed dryer, and drying coenzyme Q10 clathrate to obtain coenzyme Q10 clathrate powder.
2. The clathrate of coenzyme Q10 according to claim 1, characterized in that: the cyclodextrin is selected from one or more of beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin and gamma-cyclodextrin.
3. A solid preparation comprising the clathrate of coenzyme Q10 according to any one of claims 1 or 2, characterized in that: is one of powder, tablet, granule and capsule.
4. The solid formulation of the clathrate of coenzyme Q10 according to claim 3, characterized in that: also contains 0.1-2 weight portions of antioxidant.
5. The solid formulation of the clathrate of coenzyme Q10 according to claim 4, characterized in that: the antioxidant is selected from one or more of butylated hydroxyanisole, dibutyl hydroxytoluene, tert-butyl hydroquinone, vitamin E, rosemary extract, propyl gallate, quercetin, ascorbic acid, ascorbyl palmitate, and tea polyphenol.
6. The solid formulation of the clathrate of coenzyme Q10 according to claim 4, characterized in that: also contains one or more of 40-320 parts of filler, 3-30 parts of adhesive, 3-35 parts of wetting agent, 6-50 parts of disintegrating agent, 3-32 parts of lubricant and 6-100 parts of flavoring agent.
7. The solid preparation of the clathrate coenzyme Q10 according to claim 6, wherein: the filler is selected from one or more of microcrystalline cellulose, polyethylene glycol 4000, polyethylene glycol 6000, mannitol, sorbitol, dextrin, lactose, compressible starch and modified starch; the adhesive is selected from one or more of hydroxypropyl methylcellulose, sodium carboxymethylcellulose, polyvidone, methylcellulose, hydroxypropyl cellulose, ethyl cellulose, gelatin, carbomer or starch slurry; the wetting agent is selected from water or 30-70% ethanol water solution; the disintegrating agent is selected from one or more of crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, sodium starch glycolate, sodium carboxymethyl starch, calcium carboxymethyl cellulose and sodium alginate; the lubricant is selected from one or more of stearic acid, micronized poloxamer, sodium fumarate stearate, sodium lauryl sulfate, polyethylene glycol, sodium lauryl sulfate, magnesium lauryl sulfate, fumaric acid, sodium fumarate, talcum powder, superfine silica gel powder, magnesium stearate and silicon dioxide; the flavoring agent is one or more selected from acidic flavoring agent, sweetener, flavor enhancer, essence, natural fruit and vegetable juice powder, mucilage and milk product.
8. The solid formulation of the clathrate of coenzyme Q10 according to claim 7, characterized in that: the acidic flavoring agent is one or two of vitamin C, malic acid and citric acid; the sweetener is selected from one or more of saccharin sodium, stevioside, aspartame, neotame, honey, sucralose, sodium cyclamate, liquorice, acesulfame potassium, tagatose, disodium glycyrrhizinate, glucose, fructose, sucrose, xylitol, simple syrup and fruit syrup; the flavor enhancer is selected from one or more of sodium glutamate, aspartic acid, glycine, L-alanine, disodium succinate, disodium guanylate, disodium inosinate and chicken essence; the essence is selected from one or more of water-soluble natural essence, water-soluble synthetic essence, water-soluble natural equivalent essence and water-soluble fermented essence; the natural fruit and vegetable juice powder is selected from one or more of lemon juice powder, mint juice powder, ginger juice powder, orange juice powder, pineapple juice powder, pear juice powder, watermelon juice powder, apple juice powder, cucumber juice powder, grape juice powder, kiwi juice powder, passion fruit juice powder, strawberry juice powder, mango juice powder, sugarcane juice powder, papaya juice powder, aloe juice powder, tomato juice powder, celery juice powder, spinach juice powder, carrot juice powder, sweet pepper juice powder and green pepper juice powder; the mucilage is selected from one or more of sodium carboxymethylcellulose, methylcellulose, guar gum, acacia, tragacanth, xanthan gum, bletilla hyacinthine starch, carbomer, polyvinyl alcohol, polyvidone and gelatin.
9. A solution preparation containing the clathrate of coenzyme Q10 according to claim 1 or 2, characterized in that: also contains 1000-100000 weight parts of edible solvent.
10. The coenzyme Q10 clathrate-containing solution formulation according to claim 9, wherein: the edible solvent is selected from one or more of water, glycerol, ethanol and mannitol.
11. The coenzyme Q10 clathrate-containing solution formulation according to claim 10, wherein: also contains 0.5-10 weight portions of emulsifier and/or 6-100 weight portions of flavoring agent.
12. The coenzyme Q10 clathrate-containing solution formulation according to claim 11, wherein: the emulsifier is selected from one or more of egg yolk lecithin, soybean phospholipid, poloxamer 188, sorbitan laurate, sorbitan palmitate, sorbitan stearate, sorbitan oleate, sorbitan trioleate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, cholesterol, sodium dodecyl sulfate, sodium dodecyl benzene sulfonate, calcium dodecyl benzene sulfonate, sodium stearate, sodium oleate and sodium laurate; the flavoring agent is one or more selected from acidic flavoring agent, sweetener, flavoring agent, essence, natural fruit and vegetable juice, mucilage and milk product.
13. The coenzyme Q10 clathrate-containing solution formulation according to claim 12, wherein: the acidic flavoring agent is one or two of vitamin C, malic acid and citric acid; the sweetener is selected from one or more of saccharin sodium, stevioside, aspartame, neotame, honey, sucralose, sodium cyclamate, liquorice, acesulfame potassium, tagatose, disodium glycyrrhizinate, glucose, fructose, sucrose, xylitol, simple syrup and fruit syrup; the flavor enhancer is selected from one or more of sodium glutamate, aspartic acid, glycine, L-alanine, disodium succinate, disodium guanylate, disodium inosinate and chicken essence; the essence is selected from one or more of water-soluble natural essence, water-soluble synthetic essence, water-soluble natural equivalent essence and water-soluble fermented essence; the natural fruit and vegetable juice is selected from one or more of lemon juice, mint juice, ginger juice, orange juice, pineapple juice, pear juice, watermelon juice, apple juice, cucumber juice, grape juice, kiwi fruit juice, passion fruit juice, strawberry juice, mango juice, sugarcane juice, papaya juice, aloe juice, tomato juice, celery juice, spinach juice, carrot juice, sweet pepper juice and green pepper juice; the mucilage is selected from one or more of sodium carboxymethylcellulose, methylcellulose, guar gum, acacia, tragacanth, xanthan gum, bletilla hyacinthine starch, carbomer, polyvinyl alcohol, polyvidone and gelatin.
14. The process for preparing the clathrate of coenzyme Q10 according to claim 1 or 2, which comprises the steps of:
(1) an ultrasonic method: adding coenzyme Q10 into a saturated aqueous solution containing cyclodextrin, performing ultrasonic treatment for 5-15 minutes by using an ultrasonic disruptor to accelerate the dissolution of coenzyme Q10 to prepare an inclusion compound solution, adding a hydrophilic diluent into the inclusion compound solution, washing and drying to obtain coenzyme Q10 inclusion compound powder;
(2) saturated aqueous solution method: adding coenzyme Q10 into saturated cyclodextrin water solution, stirring with an electric stirrer at 50 deg.C for 30-60 min to accelerate the dissolution of coenzyme Q10 to obtain clathrate solution, adding hydrophilic diluent into the clathrate solution, washing, and drying to obtain coenzyme Q10 clathrate powder;
(3) grinding method: adding cyclodextrin into water, grinding with a mortar, adding ethanol solution containing coenzyme Q10 into the mortar, grinding to obtain paste, adding hydrophilic diluent into the paste, cleaning, and drying to obtain coenzyme Q10 clathrate powder;
(4) spray drying method: adding coenzyme Q10 into cyclodextrin water solution, stirring thoroughly to obtain clathrate solution with coenzyme Q10 being wrapped, adding hydrophilic diluent into clathrate solution, and drying the solution into coenzyme Q10 clathrate powder under spray condition;
(5) freeze drying: dissolving coenzyme Q10 and cyclodextrin in water, stirring to dissolve the coenzyme Q10 and the cyclodextrin to obtain an inclusion compound solution, adding a hydrophilic diluent into the inclusion compound solution, and subliming water by cooling and reducing pressure to obtain dry inclusion compound powder of coenzyme Q10;
(6) fluidized bed drying method: sequentially adding coenzyme Q10 into cyclodextrin aqueous solution, fully stirring to prepare an inclusion compound solution containing coenzyme Q10, spraying the inclusion compound solution onto a hydrophilic diluent through a fluidized bed dryer, and simultaneously drying the coenzyme Q10 inclusion compound to obtain coenzyme Q10 inclusion compound powder;
the coenzyme Q10 clathrate powder obtained above can be made into powder, tablet, granule or capsule.
15. The method for producing a solid preparation containing a clathrate of coenzyme Q10 according to any one of claims 3 to 8, characterized in that: adding one or more of antioxidant, filler, binder, wetting agent, disintegrating agent, lubricant, and correctant into the obtained clathrate powder of coenzyme Q10, mixing, and making into powder, tablet, granule or capsule.
16. The method for producing a solution preparation containing a clathrate of coenzyme Q10 according to claim 9, comprising: the method is characterized in that: adding the prepared coenzyme Q10 clathrate powder into an edible solvent, and uniformly mixing to prepare a solution;
or adding the prepared coenzyme Q10 clathrate powder, antioxidant and correctant into edible solvent, mixing, adding required emulsifier, and mixing to obtain solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810554823.7A CN108719988B (en) | 2018-05-31 | 2018-05-31 | Coenzyme Q10 clathrate and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810554823.7A CN108719988B (en) | 2018-05-31 | 2018-05-31 | Coenzyme Q10 clathrate and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108719988A CN108719988A (en) | 2018-11-02 |
| CN108719988B true CN108719988B (en) | 2022-02-15 |
Family
ID=63931469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810554823.7A Active CN108719988B (en) | 2018-05-31 | 2018-05-31 | Coenzyme Q10 clathrate and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108719988B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111374965B (en) * | 2018-12-28 | 2024-01-16 | 上海融澈水性材料有限公司 | Water-soluble coenzyme Q10 inclusion compound with high stability and preparation method thereof |
| CN110075000A (en) * | 2019-04-19 | 2019-08-02 | 山东省药学科学院 | A kind of hydroxytyrosol inclusion compound and its preparation method and application |
| CN111249249B (en) * | 2020-02-14 | 2022-06-10 | 上海宇昂水性新材料科技股份有限公司 | Coenzyme Q10 sodium alginate microspheres and preparation method thereof |
| CN112370442B (en) * | 2020-12-15 | 2022-03-01 | 浙江工业大学 | Coenzyme Q10 drug delivery system and preparation method thereof |
| CN117837754B (en) * | 2024-03-08 | 2024-05-28 | 中国农业大学 | Amorphous coenzyme Q10 with improved solubility and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1711993A (en) * | 2004-06-23 | 2005-12-28 | 昆明一尧科技开发有限公司 | Coferment Q10 microcapsule and production thereof |
| WO2005111224A3 (en) * | 2004-05-18 | 2006-06-08 | Kemijski Inst | Water-soluble coenzyme q10 in inclusion complex with beta-cyclodextrin, process of preparing, and use thereof |
| CN1870982A (en) * | 2003-10-31 | 2006-11-29 | 株式会社钟化 | Composition containing reduced coenzyme q |
| CN1981750A (en) * | 2005-12-16 | 2007-06-20 | 沈阳市万嘉生物技术研究所 | Soluble A-SH CoA-SH Q10 composition and its production |
| CN101485626A (en) * | 2009-02-11 | 2009-07-22 | 神舟天辰科技实业有限公司 | Aqueous solution containing coenzyme Q10 nano granule and preparation method thereof |
| CN101053556B (en) * | 2006-04-14 | 2010-12-08 | 沈阳市万嘉生物技术研究所 | Water soluble coenzyme Q10 hydroxyl-beta-cyclodextrin inclusion compound and its preparation method |
| CN107823168A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | A kind of rapidly-soluble tablet and preparation method thereof |
-
2018
- 2018-05-31 CN CN201810554823.7A patent/CN108719988B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1870982A (en) * | 2003-10-31 | 2006-11-29 | 株式会社钟化 | Composition containing reduced coenzyme q |
| WO2005111224A3 (en) * | 2004-05-18 | 2006-06-08 | Kemijski Inst | Water-soluble coenzyme q10 in inclusion complex with beta-cyclodextrin, process of preparing, and use thereof |
| CN1711993A (en) * | 2004-06-23 | 2005-12-28 | 昆明一尧科技开发有限公司 | Coferment Q10 microcapsule and production thereof |
| CN1981750A (en) * | 2005-12-16 | 2007-06-20 | 沈阳市万嘉生物技术研究所 | Soluble A-SH CoA-SH Q10 composition and its production |
| CN101053556B (en) * | 2006-04-14 | 2010-12-08 | 沈阳市万嘉生物技术研究所 | Water soluble coenzyme Q10 hydroxyl-beta-cyclodextrin inclusion compound and its preparation method |
| CN101485626A (en) * | 2009-02-11 | 2009-07-22 | 神舟天辰科技实业有限公司 | Aqueous solution containing coenzyme Q10 nano granule and preparation method thereof |
| CN107823168A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | A kind of rapidly-soluble tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108719988A (en) | 2018-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108719988B (en) | Coenzyme Q10 clathrate and preparation process thereof | |
| US10245238B2 (en) | Composition for oral intake | |
| KR20150057917A (en) | Composition for skin whitening | |
| CN104162168B (en) | A kind of stable paricalcitol pharmaceutical composition and preparation method thereof | |
| KR20150023059A (en) | Racecadotril liquid compositions | |
| CN109588694A (en) | The thickener composition and its preparation process of liquid viscosity can be quicklyd increase | |
| JP7057070B2 (en) | Powdered foods, methods for producing them, and methods for promoting myrosinase activity in powdered foods. | |
| JP2008521800A (en) | Dry form of water-solubilized bile acid dosage formulation, production method and use thereof | |
| KR101393438B1 (en) | A method for extracting ursolic acid from apple peels | |
| KR100923974B1 (en) | A Method for boosting biological activity in Lithospermum erythrorhizon S?et Z?extracts using irradiation | |
| KR101068266B1 (en) | A method for preparing the derivative of rhein which have a boosting anticancer activity from sennoside A using irradiation | |
| KR101774150B1 (en) | Conjugates with bovine serum albumin and ginsenosides, and uses thereof | |
| JP5742634B2 (en) | New hydroxystilbene derivatives | |
| KR101207239B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Asparagus cochinchinensis as an active ingredient | |
| JP6251862B2 (en) | ACE inhibitor | |
| JP5673025B2 (en) | New resveratrol derivatives | |
| CN106923346B (en) | Selected composite vitamin health product and application thereof | |
| JP2012236793A (en) | Ampk activator | |
| JP7337300B1 (en) | Carob polysaccharide for prevention and improvement of metabolic syndrome, method for producing the same, and use thereof | |
| CN117837754B (en) | Amorphous coenzyme Q10 with improved solubility and preparation method thereof | |
| JP5673091B2 (en) | New resveratrol derivatives | |
| JP2012092076A (en) | Novel 4-vinylphenol polymerizable compound | |
| do Nascimento Remigio et al. | Spray-Drying Microencapsulation of Phenolic Compounds from Bauhinia ungulata L. Var. Obtusifolia Aqueous Extract: A Comparative Study Using Different Wall Materials | |
| US20220211729A1 (en) | Formulations of creatine and cyclodextrin exhibiting improvd bioavailability | |
| JP2012017270A (en) | In vivo glycation inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |